CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...

CD19, a B-cell surface protein, is expressed across B-cell development and it is expressed on almost all B-cell malignancies, such as ALL, chronic lymphocytic leukemia (CLL) and several non ...

Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune ...

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free ...

The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...

DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR T-cell therapy with a 4-1BB co-stimulatory domain, which enhances ...

Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval.

Reports cash, cash equivalents and marketable securities as of December 31 were $383.5M compared to $562.7M as of December 31, 2023. Lyell ...

Cash runway is robust for now, taking CARGO Therapeutics into 2028 after a planned workforce reduction. Read why I am neutral ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate the business. The company had been planned to secure permission from ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced plans to showcase updated clinical data on its investigational CD19-CAR T cell therapy, resecabtagene autoleucel (rese-cel ...